Cambrex, an East Rutherford-based small molecule company, announced on Tuesday it has completed its biopharmaceutical expansion at its Durham, North Carolina facility.
Biopharmaceutical analysis capabilities, Cambrex said, were initially launched in Durham in 2018 and have since been expanded.
The Durham site now features a range of new capabilities which are applicable to a broad variety of biopharmaceuticals.
“The expansion began in response to a customer request to support a BioSafety Level 1 organism and grew from there based on broader customer response,” Elliott Franco, Durham site director, Cambrex, said. “We remain committed to adopting the best-in-class technologies customers need access to. Our comprehensive expertise, coupled with a transparent, safety-driven approach to implementing the new equipment, allow the Cambrex team to better serve customers across the life of their processes.”
